Cryptococcal infection in HIV-infected patients with CD4


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Aug 2021
Historique:
received: 16 07 2020
revised: 27 09 2020
accepted: 28 09 2020
pubmed: 19 10 2020
medline: 8 1 2022
entrez: 18 10 2020
Statut: ppublish

Résumé

The World Health Organization recommends routinely screening HIV-infected patients with CD4 We determined CrAg using a lateral flow assay in banked plasma from participants in the cohort of the Spanish AIDS Research Network. Eligible patients had CD4 We included 576 patients from June 2004 to December 2017. Of these, 43 were CrAg+ for an overall prevalence of 7.5%. There were no differences depending on birthplace. The CrAg+ was independently associated with a higher mortality at eight weeks (hazard ratio (HR) 5.36, 95% confidence interval (CI) 1.46-19.56) and 6 months (HR 3.12, 95% CI 1.19-8.21). CM was reported in 10 of the 43 CrAg+ patients. There were no cases among negatives. Five patients had CM when the plasma was collected and five developed it during the follow-up. The number of subjects needed to screen to anticipate the diagnosis of one CM case was 114. The CrAg+ prevalence among HIV-infected patients with CD4

Identifiants

pubmed: 33069858
pii: S1198-743X(20)30607-8
doi: 10.1016/j.cmi.2020.09.053
pii:
doi:

Substances chimiques

Antifungal Agents 0
Antigens, Fungal 0

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1171.e1-1171.e7

Informations de copyright

Copyright © 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

María Asunción Pérez-Jacoiste Asín (MA)

Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain. Electronic address: mperezja82@hotmail.com.

Otilia Bisbal (O)

HIV Unit, Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.

José Antonio Iribarren (JA)

Department of Infectious Diseases, Hospital Universitario Donostia, Instituto BioDonostia, San Sebastián, Spain.

Alfredo Pérez-Rivilla (A)

Department of Microbiology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Rafael Mican (R)

HIV Unit, Department of Internal Medicine, Hospital Universitario La Paz, Instituto de Investigación Hospital Universitario La Paz (IdiPAZ), Madrid, Spain.

Fernando Dronda (F)

Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.

Carmen María González-Domenech (CM)

Biomedical Research Institute of Malaga, Clinical Microbiology and Infectious Diseases Unit, Hospital Virgen de la Victoria, Málaga, Spain.

David Vinuesa-García (D)

Department of Infectious Diseases, Hospital Clínico San Cecilio, Granada, Spain.

Juan Macías (J)

Department of Infectious Diseases, Hospital Nuestra Señora de Valme, Sevilla, Spain.

Carlos Lumbreras (C)

Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Madrid, Spain.

Santiago Moreno (S)

Department of Infectious Diseases, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Universidad de Alcalá, Madrid, Spain.

Rafael Rubio (R)

HIV Unit, Department of Internal Medicine, Hospital Universitario 12 de Octubre, Instituto de Investigación Hospital 12 de Octubre (imas12), Department of Medicine, School of Medicine, Universidad Complutense, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH